<tbody id="jftbj"></tbody>

              A LONG-TERM FOCUS
              ON INNOVATION

              We welcome the opportunity to discuss:

              BUSINESS
              DEVELOPMENT
              COLLABORATIONS

              • In-licensing and / or R&D collaborations
                • Creative collaborations in emerging fields
                • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
              • Strategic late-stage development and commercial partnerships with other leading biopharma companies
              • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

              Introduce your assets or discuss
              late-stage partnership

              ACADEMIC &
              RESEARCH
              COLLABORATIONS

              • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

              Learn more

              • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

              Learn more

              OUR BUSINESS DEVELOPMENT STRATEGY

              Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

              We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

              • Novel platforms that enable next-generation therapeutics
              • Technologies for antibody discovery and development against new / challenging targets
              • New approaches that enhance activity of tumor-directed antibodies
              • Biomarker discovery and validation
              • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
              • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
              • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

              SOME OF OUR CURRENT COLLABORATORS INCLUDE:


              Bayer logo

              Global ophthalmology
              collaborations

              Sanofi logo

              Antibody and immunotherapy
              collaborations

              Icahn School of Medicine logo

              Antibody discovery
              agreement

              Columbia University logo

              Research collaboration on genetic
              basis of familial disease

              Teva logo

              Global collaboration for
              investigational pain therapeutic

              Intellia Therapeutics logo

              Gene-editing technology
              collaboration

              Adicet Bio logo

              Engineered immune cell
              therapeutics collaboration

              Alnylam logo

              RNA interference (RNAi)
              therapeutics collaboration

              伊人久久大香线蕉综合